Answers are grounded in this paper and cite their sources.
Objective The study aimed to translate and culturally adapt the ABCD-2 into Greek and investigate its discriminative ability in four neurodegenerative-disorder groups against healthy controls.Methods About 315 participants, assigned into five diagnostic groups [Parkinson’s Disease (PD, n = 57), Alzheimer’s Disease (AD, n = 62), Mild Cognitive Impairment (MCI, n = 67), Mixed Dementia (MD, n = 18), and a Control Group (CG, n = 111)], were assessed with the ABCD-2 and Addenbrooke’s Cognitive Examination-Revised (ACE-R) for convergent-validity comparison.Results Kruskal–Wallis tests showed significant group differences across all cognitive-communication domains (p < 0.001). The ABCD-2 Total Score showed excellent discrimination between patients and controls (AUC = 0.935, 95% CI 0.909–0.960; sensitivity = 85.8%, specificity = 89.2% at a cutoff of 25.2). Differential diagnostic accuracy was moderate-to-good for AD (AUC = 0.783) and MCI (AUC = 0.788), but limited for PD (AUC = 0.530) and MD (AUC = 0.620). Language Expression (AUC = 0.916) and Episodic Memory (AUC = 0.888) showed the highest diagnostic utility. The Total Score correlated strongly with the ACE-R (ρ = 0.888, p < 0.001), with excellent inter-rater reliability (ICC(2,1) = 0.997, 95% CI 0.989–0.999) and high internal consistency (Cronbach’s α = 0.92).Conclusions The Greek version of the ABCD-2 is a reliable and valid battery for identifying cognitive-communication deficits in neurodegenerative conditions. Its discriminative validity may support the detection and individualized management of cognitive-communication disorders in these populations. Subgroup-specific and unadjusted cutoff scores should be regarded as exploratory pending external validation.
No takes yet. Share an insight, caveat, or question.
Πιτοπούλου et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: